NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.
Employees - 11,
CEO - Ronen Twito,
Sector - Healthcare,
Country - CH,
Market Cap -
Altman ZScore(max is 10): -30.42, Piotroski Score(max is 10): 2, Working Capital: $2580766, Total Assets: $4337628, Retained Earnings: $-74805306, EBIT: -10009498, Total Liabilities: $1455121, Revenue: $0
AryaFin Target Price - $10.79 - Current Price $ - Analyst Target Price $
| Ticker | NCEL |
| Index | |
| Curent Price | |
| Change | |
| Market Cap | |
| Average Volume | |
| Income | |
| Sales | |
| Book Value/Share | |
| Cash/Share | |
| Dividend Est | |
| Dividend TTM | |
| Dividend Ex-Date | |
| Employees | |
| Moving Avg 20days | |
| Moving Avg 50days | |
| Moving Avg 200days | |
| Shares Outstanding | |
| Earnings Date | |
| Inst. Ownership |
| Price/Earnings | |
| Forwad P/E | |
| PE Growth | |
| Price/Sales | |
| Price/Book | |
| Price/Cash | |
| Price/FCF | |
| Quick Ratio | |
| Current Ratio | |
| Debt/Equity | |
| Return on Assets | |
| Return on Equity | |
| Return on Investment | |
| Gross Margin | |
| Ops Margin | |
| Profit Margin | |
| RSI | |
| BETA(β) | |
| From 52week Low | |
| From 52week High |
| EPS | |
| EPS next Year | |
| EPS next Qtr | |
| EPS this Year | |
| EPS next 5 Year | |
| EPS past 5 Year | |
| Sales past 5 Year | |
| EPS Y/Y | |
| Sales Y/Y | |
| EPS Q/Q | |
| Sales Q/Q | |
| Sales Surprise | |
| EPS Surprise | |
| ATR(14) | |
| Perf Week | |
| Perf Month | |
| Perf Quarter | |
| Perf Year | |
| Perf YTD | |
| Target Price |
AryaFin Engine© - An AI FinTech Venture - 2024-26 Disclaimer